Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 29020359.
- Also identified by DOI 10.1093/cid/cix787.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We assessed the effectiveness and safety of sofosbuvir (SOF) combined with ledipasvir (LDV) or daclatasvir (DCV) in 12 heart transplant recipients with chronic hepatitis C virus (HCV). The sustained virologic response (SVR12) rate was 100% [95% confidence interval [CI]: 75.8%-100%]. All patients tolerated treatment well without interruption, death, or serious adverse events.
Medical subject headings
- Antiviral Agents
- Benzimidazoles
- Fluorenes
- Heart Transplantation
- Hepatitis C, Chronic
- Imidazoles
- Sofosbuvir
- Transplant Recipients